(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
02 October 2025 (02.10.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/207643 A1

(51) International Patent Classification:
A61K 31/506 (2006.01) *A61P 35/00* (2006.01)
A61K 31/519 (2006.01)

(21) International Application Number:
PCT/US2025/021356

(22) International Filing Date:
25 March 2025 (25.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/570,700 27 March 2024 (27.03.2024) US
63/574,159 03 April 2024 (03.04.2024) US

(71) Applicant: **ALTEROME THERAPEUTICS, INC.** [US/US]; 13480 Evening Creek Drive North, Suite 450, San Diego, California 92128 (US).

(72) Inventors: **MURPHY, Eric Anthony**; 13480 Evening Creek Drive North, Suite 450, San Diego, California 92128 (US). **CHI, Andrew**; 13480 Evening Creek Drive North, Suite 450, San Diego, California 92128 (US). **GARDINER, Elisabeth**; 13480 Evening Creek Drive North, Suite 450, San Diego, California 92128 (US). **GORNEY, Vanessa**; 13480 Evening Creek Drive North, Suite 450, San Diego, California 92128 (US). **IBANEZ, Maureen**; 13480 Evening Creek Drive North, Suite 450, San Diego, California 92128 (US). **KANG, Vicky**; 13480 Evening Creek Drive North, Suite 450, San Diego, California 92128 (US). **PEREZ, Michelle**; 13480 Evening Creek Drive North, Suite 450, San Diego, California 92128 (US). **SMITH, Troy**; 13480 Evening Creek Drive North, Suite 450, San Diego, California 92128 (US). **TIMPLE, Noel**; 13480 Evening Creek Drive North, Suite 450, San Diego, California 92128 (US). **WANG, Tim Sen**; 13480 Evening Creek Drive North, Suite 450, San Diego, California 92128 (US).

(74) Agent: **CLARK, David** et al.; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94304 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: TREATMENT OF CANCER WITH AN AKT1 INHIBITOR

Fig. 1

A.



(57) Abstract: Provided herein are compositions and methods for the treatment of cancer. Said compositions comprise a AKT1 inhibitor. Some embodiments comprise combination therapy featuring the AKT1 inhibitor with at least one additional oncology therapeutic agent.

WO 2025/207643 A1

[Continued on next page]

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*